Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18040277 | 0.84 | RAB9A (0.59) | RAB9ANPC1IDO1AKR1C3LOXL2 | |
| SCHEMBL10864161 | 0.82 | IDO1 (0.57) | RAB9ANPC1IDO1AKR1C3LOXL2 | |
| SCHEMBL7047908 | 0.80 | IDO1 (0.63) | RAB9ANPC1IDO1AKR1C3LOXL2 | |
| SCHEMBL5278978 | 0.78 | IDO1 (0.56) | RAB9ANPC1IDO1AKR1C3LOXL2 | |
| SCHEMBL14042050 | 0.77 | IDO1 (0.59) | RAB9ANPC1IDO1AKR1C3LOXL2 | |
| SCHEMBL10106824 | 0.77 | IDO1 (0.59) | RAB9ANPC1IDO1AKR1C3LOXL2 | |
| Bicarbonate SCHEMBL7693242 | 0.77 | IDO1 (0.59) | RAB9ANPC1IDO1AKR1C3LOXL2 | |
| SCHEMBL37665 | 0.77 | AKR1C3 (0.62) | RAB9ANPC1IDO1AKR1C3MAOB | |
| SCHEMBL16195828 | 0.77 | RAB9A (0.51) | RAB9ANPC1MAOBMAPT | |
| SCHEMBL8770420 | 0.76 | IDO1 (0.54) | RAB9ANPC1IDO1AKR1C3LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940916-B1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LTD (AU) | 2016-12-14 | — | — | EP | claimed |
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | claimed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | claimed |
| CN-115260211-B | Thiophene condensed ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-115260211-A | Thiophene fused ring containing derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-109593096-B | Tricyclic heterocycles as BET protein inhibitors | 因赛特公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-2052011-B1 | TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT | STARPHARMA PTY LTD (AU) | 2020-11-04 | — | — | EP | disclosed |
| EP-1940916-B1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LTD (AU) | 2016-12-14 | — | — | EP | disclosed |
| US-9127130-B2 | Polylysine dendrimer contrast agent | STARPHARMA PTY LTD. (AU) | 2015-09-08 | — | — | US | disclosed |
| US-8586705-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-8420067-B2 | Targeted polylysine dendrimer therapeutic agent | STARPHARMA PTY LTD (AU) | 2013-04-16 | — | — | US | disclosed |
| US-20100278750-A1 | POLYLYSINE DENDRIMER CONTRAST AGENT | STARPHARMA PTY LTD | 2010-11-04 | — | — | US | disclosed |
| WO-2009103123-A1 | DENDRIMERIC ENZYME INHIBITORS | STARPHARMA PTY LIMITED (AU) | 2009-08-27 | — | — | WO | disclosed |
| EP-2076557-A1 | POLYLYSINE DENDRIMER CONTRAST AGENT | Starpharma Pty Ltd (AU) | 2009-07-08 | — | — | EP | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| EP-2052011-A1 | TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT | Starpharma Pty Ltd (AU) | 2009-04-29 | — | — | EP | disclosed |
| EP-1940916-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | Starpharma Pty Limited (AU) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008017125-A1 | TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT | STARPHARMA PTY LTD (AU) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017122-A1 | POLYLYSINE DENDRIMER CONTRAST AGENT | STARPHARMA PTY LTD (AU) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007048190-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278750-A1 | POLYLYSINE DENDRIMER CONTRAST AGENT | PARG, PARN, TLR3 | RAB9A 2169/4885NPC1 1297/4885IDO1 967/4885 |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | MICA, PICALM, CLTB | RAB9A 4358/4885NPC1 1131/4885IDO1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.